Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.

Journal of translational medicine - 15 Jun 2023

Kurnellas Michael, Mitra Ananya, Schwabe Tina, Paul Robert, Arrant Andrew E, Roberson Erik D, Ward Michael, Yeh Felix, Long Hua, Rosenthal Arnon

Abstract excerpt

BACKGROUND: Heterozygous loss-of-function mutations in the progranulin (PGRN) gene (GRN) cause a reduction in PGRN and lead to the development of frontotemporal dementia (FTD-GRN). PGRN is a secreted lysosomal chaperone, immune regulator, and neuronal survival factor that is shuttled to the lysosome through multiple receptors, including sortilin. Here, we report the characterization of latozinemab, a human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Frontotemporal Dementia
Share to Intercellular Signaling Peptides and Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Progranulins

Source

Open in PubMed Open full text

Identifiers

PMID: 37322482
DOI: 10.1186/s12967-023-04251-y
PMCID: PMC10268535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.PMID 37322482Read ↗

Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementiaSemantic proximity Read ↗

Anti-sortilin1 Antibody Up-Regulates Progranulin via Sortilin1 Down-RegulationSemantic proximity Read ↗

Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency.Semantic proximity Read ↗

Clinical investigation of VES001, a novel oral small molecule sortilin receptor inhibitor, for the treatment of frontotemporal dementiaSemantic proximity Read ↗

Potential mechanisms of progranulin-deficient FTLD.Semantic proximity Read ↗

Frontotemporal dementia as a consequence of GRN mutations: From disease cause to models to therapies.Semantic proximity Read ↗

Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.Semantic proximity Read ↗

Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals.Semantic proximity Read ↗

New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia.Semantic proximity Read ↗

Progranulin and TMEM106B: when two become wan.Semantic proximity Read ↗

Progranulin: an emerging target for FTLD therapies.Semantic proximity Read ↗

C-Terminus of Progranulin Interacts with the Beta-Propeller Region of Sortilin to Regulate Progranulin TraffickingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.